Sotyktu
My Prescription
Payment
Select pharmacy
$6,521.36
$30.00 due at pharmacy
$6,521.36 - $30.00 = $6,491.36
$6,491.36 remaining balance
You will be given your coupon after you complete your purchase with PayPal.
WalgreensPowered by$6,521.36
Print or send this coupon to your phone
WalgreensPowered byAbout Sotyktu
Drug Details
Deucravacitinib, marketed under the brand name Sotyktu, is a prescription medication used to treat moderate to severe plaque psoriasis in adults. This condition is characterized by red, thickened, and scaly patches on the skin. Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor, which works by targeting a specific enzyme in the Janus kinase family that is responsible for causing inflammation in the body. By inhibiting this enzyme, the medication helps to reduce the symptoms of psoriasis. It is taken orally in tablet form once daily. While effective, patients should be aware of potential side effects, including an increased risk of infections, such as upper respiratory infections and herpes simplex. As with all medications, it is important to consult with a healthcare professional to ensure it is safe and appropriate for individual use.
Price history for Sotyktu
30 Tablets, 6MG
Average retail price for Sotyktu
Average SaveHealth price for Sotyktu
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Sotyktu dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 6MG | 30 Tablets | $6,521.36 | $217.38 |
Sotyktu FAQs
Sotyktu and Otezla are not the same. They are both medications used to treat certain conditions, but they have different active ingredients and mechanisms of action. Sotyktu contains the active ingredient deucravacitinib, while Otezla contains apremilast. It is important for patients to follow their healthcare provider's guidance regarding which medication is appropriate for their specific condition.
Sotyktu is expensive due to several factors, including the costs associated with research and development, clinical trials, regulatory approvals, and marketing. Additionally, the pricing may reflect the drug's effectiveness, the complexity of its production, and the lack of generic alternatives. Pharmaceutical companies also consider the potential market size and the need to recoup investments made during the drug's development.
Yes, Sotyktu (deucravacitinib) can weaken the immune system. It is an oral medication used to treat certain autoimmune conditions, and it works by modulating the immune response. As a result, it may increase the risk of infections. It is important for patients to discuss potential risks and benefits with their healthcare provider.
Sotyktu (deucravacitinib) is a medication approved for the treatment of moderate to severe plaque psoriasis in adults. Clinical trials have demonstrated its effectiveness in reducing the severity of psoriasis symptoms. However, individual responses to the medication can vary, and it is important for patients to discuss with their healthcare provider whether Sotyktu is an appropriate treatment option for their specific condition.
Weight loss is not commonly reported as a side effect of Sotyktu (deucravacitinib). If a patient experiences unexpected weight changes while taking this medication, it is advisable to consult with a healthcare provider for further evaluation.